Arbidol analogs are primarily explored for their antiviral properties, particularly in the treatment of respiratory infections caused by influenza and other viruses. They function by inhibiting viral fusion with host cell membranes, thereby preventing viral entry and replication. This mechanism makes them promising candidates for developing broad-spectrum antiviral therapies. Research is ongoing to evaluate their efficacy against emerging viral strains, including coronaviruses, due to their potential to disrupt viral envelope interactions. Additionally, these analogs are being studied for their immunomodulatory effects, which could enhance the body's immune response to infections. Their application extends to prophylactic use, where they may reduce the risk of infection in high-risk populations.